PTLA News and Press, Portola Pharmaceuticals Inc. From 11/05/19

Portola Pharmaceuticals, Inc. (PTLA) Q3 2019 Earnings Conference Call November 05, 2019 4:30 PM ET Company Participants Jennifer Zibuda – Investor Relations Scott Garland – President and Chief Executive Officer Mardi Dier – Chief Financial and Chief Business ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q3 Non-GAAP EPS of -$0.53 beats by $0.34 ; GAAP EPS of -$0.68 beats by $0.20 . Revenue of $36.8M (+159.2% Y/Y) beats by $2.16M . Shares +0.8% . Press Release More news on: Portola Pharmaceuticals, Inc., Earnings news and commentary, Heal...

SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of strong Andex...

ACHC , AINV , AIZ , AKCA , ALRM , ANDE , ATUS , AVLR , BEAT , BTG , CARG , CCRN , CDK , CENX , CGBD , CMP , CNO , COHR , CPSI , CSOD , CWK , CZR , DEI , DVA , DVN , ES , EVH , EVRI , FANG , FATE , FIVN , FLDM , FRGI , FTR , GHL , GPRE , GTE , GTES , GW...

SOUTH SAN FRANCISCO, Calif. , Oct. 28, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b /4 trial of its Factor Xa inhibitor antidote Andexxa ® [coag...

Investment Thesis Portola has experienced plenty of highs and lows and that has been reflected in a share price that has risen as high as $66 (in July 2017) but has since dwindled to just under $29. Arguably however, the company's prospects look better now that at any stage in its history....

Portola Pharmaceuticals (NASDAQ: PTLA) might be relatively unheard of compared to its more popular peers. However, the $2.1 billion biotech stock has some promising drug candidates in the pipeline, with at least one poised to become a major blockbuster. Over the past couple of years, Porto...

SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019 , and provide a general bus...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad-hoc quer...